While the IRB approval is a positive catalyst moving NASARIX™ closer to clinical data, site-specific approvals are still needed before enrollment begins. Traders should monitor for site activation announcements and first patient dosed, which would be the next material catalyst.
Price Chart
Executive Summary
Polyrizon announced receipt of central IRB approval (BRANY, granted June 18, 2026) to begin its first human clinical trial for NASARIX™, a nasal spray for seasonal allergic rhinitis. This is a regulatory milestone for the development-stage biotech, but site-specific approvals are still needed before enrollment can begin, and no financial or timeline data were disclosed.
Key Facts
- Received central IRB approval from BRANY on June 18, 2026, for NASARIX™ first-in-human clinical trial (protocol PL14-CTP-01).
- The trial compares NASARIX™ to saline spray for seasonal allergic rhinitis, assessing efficacy, safety, and tolerability.
- Central IRB approval is for the master protocol; individual clinical sites still need separate site-specific approvals before patient enrollment.
- IRB approval valid through June 17, 2027, subject to ongoing oversight.
- Polyrizon is a development-stage biotech with a market cap of approximately $21M.
Financial Impact
No financial figures disclosed in the filing. As a development-stage company with no approved products or revenue, the milestone has no quantifiable financial impact yet.
Risk Factors
- Clinical trial failure or delay in obtaining site-specific approvals could reverse any positive sentiment.
- As a pre-revenue biotech with no marketed products, the stock is highly speculative and subject to binary outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-073097 |
| Document: ea029624301ex99-1.htm | 0001213900-26-073097 |
| Document: 0001213900-26-073097-index-headers.html | 0001213900-26-073097 |
| Document: 0001213900-26-073097-index.html | 0001213900-26-073097 |
| Document: 0001213900-26-073097.txt | 0001213900-26-073097 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $9.01 | awaiting T+1 | awaiting T+1 | $8.58 (−4.77%) |
Oct 27, 2026 today | Press Release | $9.01 | awaiting T+1 | awaiting T+1 | $8.58 (−4.77%) |
Oct 5, 2026 22d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.58 (−11.27%) |
Oct 2, 2026 26d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.58 (+10.72%) |
Sep 22, 2026 5w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.58 (−19.51%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.58 (+21.28%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.58 (+23.67%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.58 (−16.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers